The assumption that improved tumor exposure might lead to greater efficacy of AZD8701 is supported by the immunological effects observed in the periphery, specifically the increased levels of Ki67+ CD8 T cells in the blood (Fig. 4D), which indicate T-cell activation. The gene discussed is CD8A; the disease is neoplasm.